Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ADC Therapeutics SA

ADCT ✗ NOT COMPLIANT ☆ Track — members

NYSE · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.01

▼ -3.81%

Market Cap $128.94M · Vol 675.49K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$128.94M

Micro Cap

Div Yield

N/A

EPS Growth

+23.93%

YoY

RSI (14)

38.60

Momentum

Beta

1.81

vs Market

52W High

$4.97

79.68% below

52W Low

$0.78

29.55% above

Volume

675.49K

Avg 299.70K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

84.55%

Public shares

Shariah Compliance8 STANDARDS

✗ ADC Therapeutics SA (ADCT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ADCT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.62%

-17.89%

-69.94%

-74.69%

YTD

-71.39%

-68.34%

-36.88%

-96.23%

Financials & Valuation

TTM · Annual

Total Revenue	$81.36M
Net Income	$-142,623,000.00
Revenue Growth (YoY)	+2.17%
Gross Margin	92.87%
Operating Margin	-133.21%
Net Profit Margin	-175.31%
ROE	N/A
ROA · ROIC	-43.90% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5.51
P/B	N/A
P/FCF	N/A
EPS Growth	+23.93%
Outstanding Shares	127.67M

Technical Indicators

50-Day SMA	$1.15
200-Day SMA	$3.19
RSI (14)	38.60
Beta	1.81
52-Week High	$4.97
52-Week Low	$0.78

Volume Today	675.49K
Avg Daily Volume (30D)	299.70K
Relative Volume	2.25x
Volatility (10D)	94.73
Volatility (30D)	73.88
Free Float	84.55%

Analyst Consensus

BUY

Current Price $1.01

Mean Target $2.63

52W Low$0.78 52W High$4.97

Current

Target

$0.78 $4.97

Current Analyst target

+159.90% upside potential · 5 analysts

Identifiers

ExchangeNYSE

FIGIBBG00Q6Q3RN0

ISINCH0499880968

CountrySwitzerland

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 8, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.